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Coenzyme Q10MELAS syndrome is amitochondrial disorder that is causedmainly by them.3243ANGmutation inmitochondrial
DNA. Here, we report on how the severity of pathophysiological alterations is differently expressed in ﬁbroblasts
derived from patients with MELAS disease. We evaluated mitophagy activation and mitochondrial biogenesis
which are the main mechanisms regulating the degradation and genesis of mitochondrial mass in MELAS ﬁbro-
blasts and transmitochondrial cybrids. Our results suggest a critical balance between mitophagy and mitochon-
drial biogenesis which leads to the expression of different degrees of pathological severity among MELAS
ﬁbroblast cell lines according to their heteroplasmy load and the activation of AMP-activated protein kinase
(AMPK). AMPK-activators such as 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) or coen-
zyme Q10 (CoQ) increased peroxisome proliferator-activated receptor alpha (PGC-1α) nuclear translocation,mi-
tochondrial biogenesis, antioxidant enzyme system response, autophagic ﬂux and improved pathophysiological
alterations in MELAS ﬁbroblasts with the most severe phenotype. Our ﬁndings support the hypothesis that
mitochondrial biogenesis, increased antioxidant response and autophagy clearance serve as compensatory
mechanisms in response to mitophagic degradation of dysfunctional mitochondria and point out that AMPK is
an important player in this balance.
© 2015 Elsevier B.V. All rights reserved.amide 1-β-D-ribofuranoside;
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MELAS (mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) syndrome is a genetically and clinically heteroge-
neous mitochondrial disorder which is associated with neurologic
symptoms such as seizures, encephalopathy and stroke-like episodes
and other secondarymanifestations such as short stature, cognitive dys-
function, migraine, depression, cardiomyopathy and diabetes mellitus
[1–4]. Although there are at least 29 speciﬁc mutations reported, 80%
of MELAS patients harbour a transition of adenine to guanine in the
3243 position in the tRNALeu (UUR) gene of mtDNA (MT-TL1 gene). The
mutation affects the modiﬁcations of the wobble U base that impairs
translation at UUA and UUG codons, deriving in defective incorporation
of amino acids inmitochondrial proteins encoded bymtDNA [5]. Partic-
ularly, proteins rich in codons UUG, like ND6 subunit of complex I, are
mainly affected [6,7]. Thus, MELAS disease is often associated with a
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drial respiratory chain defects [8,9].
The A3243G mutation induces high rate of glycolysis followed by
lactic acid accumulation, diminished pyruvate oxidation by mitochon-
dria, reduced mitochondrial membrane potential (ΔΨm), decreased
ATP production, altered cellular calcium homeostasis, high production
of reactive oxygen species, Diabetes Mellitus (by impaired insulin secre-
tion), early aging, and dysregulation of genes involved in the biosynthe-
sis of amino groups and urea [10–12].
Recently, both autophagy and mitophagy have been implicated in
the pathophysiology of mitochondrial diseases [13,14]. Autophagy is
an evolutionarily conserved process that is responsible for the bulk
degradation of cytoplasmic components, including entire organelles as
mitochondria, via the lysosomal pathway [15]. On the other hand, the
term mitophagy describes the selective sequestration and subsequent
degradation of dysfunctional mitochondria [16]. Mitophagy and mito-
chondrial biogenesis are the main mechanisms regulating the degrada-
tion and genesis of mitochondrial mass.
In previous works we have demonstrated that mitophagy and
impaired autophagic ﬂux play a central role in the pathophysiological
alterations found in ﬁbroblasts derived from MELAS patients [13,17].
Induction of mitophagy results in the speciﬁc elimination of dysfunc-
tional mitochondria in MELAS ﬁbroblasts. Thus, damaged mitochondria
are selectively degraded by mitophagy, ensuring the maintenance of a
functional mitochondria population.Mitophagy depends on the general
autophagic components and is activated in response to general signals,
including nutrient deprivation and oxidative stress, or speciﬁc signals
like mitochondrial damage. In mammals, new autophagic process-
related proteins like NIX, participate like a receptor interacting with
LC3 and GABARAP [18], or Parkin which seems to point up to the
autophagic selectivity translocating to depolarized mitochondria [19].
This selective tagging of depolarized mitochondria induces the forma-
tion of a double membrane which circled the damaged mitochondria
and generates the autophagosome [16,20]. Atg12–Atg5 is an essential
protein complex required to elongation of the autophagosome [21–23]
as well as LC3, acting as a microtubular-autophagosome adaptor, is a
necessary protein for themovement of autophagosomes alongmicrotu-
bules to the lysosomes in the perinuclear zone of the cells to generate
the autolysosome [24]. The autophagic adaptor p62/SQSTM1 links
with LC3 and ubiquitin residues of tagged proteins by Parkin [25,26].
On the other hand, mitochondrial biogenesis is a complex process
mediated by the coordinated transcription and translation of nuclear
and mitochondrial genes, the protein transport from cytosol to
mitochondria and the mitochondrial turnover [27]. Mitochondrial
biogenesis in turn includes two processes, the proliferation and the dif-
ferentiation whereby mitochondria get their structural and functional
characteristics [28]. Peroxisome proliferator-activated receptor gamma
coactivator 1alpha (PGC-1α) is a metabolic regulator that coactivates
the transcriptional activity of nuclear respiratory factors NRF1 and
NFR2 and induces mitochondrial transcriptional factor A (mtTFA)
expression [29]. This cascadeﬁnisheswithmtDNA replication andmito-
chondrial ﬁssion [30,31]. One of the key proteins of the PGC-1α activa-
tion is 5′AMP-activated protein kinase (AMPK) which binds directly
PGC-1α and phosphorylates it [32].
MELAS syndrome has no cure but there are palliative treatments of
the symptoms at the cardiac, renal, growth and nutritional level. The
most common pharmacological treatment is usually based in cocktails
of different drugs combining several strategies that can improve patient
health [33]. Recently, our group has shown that the treatment with
riboﬂavin or coenzyme Q10 (CoQ) improved the pathophysiological
alterations in MELAS cell models [17].
Furthermore, recent evidences on the role of mitochondrial biogen-
esis in mitochondrial diseases are bringing to light new target proteins
like AMPK and thus, it has been reported that drugs such as metformin
or 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR)
are the most beneﬁcial compounds in Complex I deﬁcient patient'sﬁbroblasts [34]. Moreover, there are evidences that many beneﬁcial ef-
fects of CoQ supplementation aremediated byAMPK activation [35–37].
In this work, we examined the balance betweenmitophagy and mi-
tochondrial biogenesis in four MELAS ﬁbroblast cell lines and MELAS
cybrids, and the efﬁciency of AMPK activators, such as AICAR and CoQ,
in the improvement of the pathophysiological alterations associated
with the disease.
2. Material and methods
2.1. Reagents
We purchased the following antibodies and chemicals: Monoclonal
Anti-Actin antibody, Anti-α-tubulin, compound C, CoQ, AICAR and
trypsin-EDTA solution from Sigma-Aldrich (St. Louis, MO, USA); Mono-
clonal antibodies speciﬁc for oxidative phosphorylation, complex III
(Core 1 subunit), complex II (30 kDa subunit I), MitoSOXTM, 10-N-
nonyl acridine orange, TMRE (Tetramethylrhodamine Ethyl Ester),
MitoTracker, LysoTracker, Hoechst 3342 from Invitrogen/Molecular
Probes (Eugene, OR, USA); Anti-cytochrome c antibodies from BD
Biosciences Pharmingen (San Jose, CA, USA). Anti-GAPDH monoclonal
antibody, clone 6C5 from Calbiochem-Merck Chemicals Ltd. (Notting-
ham, UK); Anti-hATG12 from Biosensis (South Australia, Australia);
Anti-MAP LC3 (N-20), anti-catalase (H-300), anti-Cathepsin D, anti-
PGC-1α, anti-mtTFA, anti-NFR1, anti-ULK1, anti phospho-ULK1 and
anti-AMPK from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
Anti-phospho-AMPK and Anti-Phospho-PGC-1α from R&D System
(Minneapolis, MN, USA); Anti Mn-SOD from Cell Signaling Technology
(Danvers, MA, USA); a cocktail of protease inhibitors from Boehringer
Mannheim (Indianapolis, IN, USA); and Immun Star HRP substrate kit
from Bio-Rad Laboratories Inc. (Hercules, CA, USA). All other chemicals
were purchased from Sigma-Aldrich.
2.2. Fibroblast cultures
Samples from patients and controls were obtained according to the
Helsinki Declarations of 1964, as revised in 2001. Cultured ﬁbroblasts
were derived from skin biopsies of four patients (MELAS 1, MELAS 2,
MELAS A andMELAS B) carrying a heteroplasmicm.3243ANGmutation.
The heteroplasmy load analysis showed that MELAS 1 and MELAS 2
harboured highermutation load thanMELAS A andMELAS B ﬁbroblasts
(MELAS 1: 17%, MELAS 2: 26%, MELAS A: 9% andMELAS B: 4%). We ver-
iﬁed that heteroplasmy load did not shift signiﬁcantly during this work.
Age-/sex-matched control ﬁbroblasts, at similar low passage number
were derived from two healthy volunteers.When indicated in theﬁgure
legends, control data were shown as a mean of two control ﬁbroblast
cultures. Fibroblasts from theMELAS patient and controlswere cultured
at 37 °C in DMEM containing 4.5 g/L glucose, L-glutamine, and pyruvate
supplemented with an antibiotic/antimycotic solution and 20% fetal
bovine serum.
2.3. Construction of transmitochondrial cybrid cell lines
143B osteosarcoma cybrid clones were generated as previously
described [17]. Control osteosarcoma cybrid cells (100% wild-type)
and cybrid cells carrying them.3243ANGmutation (90% heteroplasmy)
were cultured in DMEM containing 4.5 g/L glucose, supplemented with
5% FBS, sodium pyruvate (100 μg/ml), uridine (50 μg/ml), penicillin
(100 IU/ml) and streptomycin (100 μg/ml). Heteroplasmy load in
MELAS cybrids did not shift signiﬁcantly during the study. To induce
respiration and make more evident the mitochondrial defects, cybrids
clones were cultured in a glucose-restricted medium using DMEM
2.5 g/L glucose, L-glutamine (GIBCO Life technologies, UK) supplement-
ed with 1% antibiotic/antimycotic solution (PAA Laboratories GmbH,
Austria) and uridine 50 μg/ml (Sigma-Aldrich) and 2% fetal bovine
serum (PAA Laboratories GmbH, Austria).
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Heteroplasmywas determined by PCR-RFLP. DNA ampliﬁcation was
performed by using reverse primer 5′-AGTAATGTTGATAGTAGAAT-3′
and forward primer 5′-ATTTATTAATGCAAACAGTA-3′. PCR conditions
for all reactions were 94 °C for 5 min, 35 cycles with denaturation at
94 °C for 35 s, annealing at 55 °C for 35 s and elongation at 72 °C for
1 min; 1 cycle at 72 °C for 7 min, and a ﬁnal hold at 4 °C. After PCR,
the amplicon was digested with Apa I (Fermentas, Burlington, Ontario,
Canada) for 5 h 37 °C and DNA fragments were separated in 1% agarose
gel. Gels stained with RedSafe Nucleic Acid Staining Solution (iNtRON
Biotechnology, Inc., Korea) were placed on a UV light transilluminator
and PCR and digested products were visualized. The bands were
analyzed using ImageJ software.2.5. Cells treatment
Fibroblasts and transmitochondrial cybrids were treated with
100 μM CoQ, 100 μM AICAR. Fibroblasts were exposed to these drugs
during 1 week whereas the cybrid cells were incubated during 48 h.
The pharmacological inhibition of AMPK was achieved with 10 μM
compound C supplementation 12 h before harvesting the cells. The
pharmacological inhibition of autophagy ﬂux was achieved with
100 nM Baﬁlomycin A1 supplementation 12 h before harvesting the
cells.2.6. Mitochondrial respiratory chain enzyme activities
Activities of NADH:coenzyme Q1 oxidoreductase (complex I), succi-
nate dehydrogenase (complex II), cytochrome c oxidase (complex IV),
ubiquinol:cytochrome c oxidoreductase (complex III), NADH: cyto-
chrome c reductase (complex I+ III), succinate:cytochrome c reductase
(complex II + III) were determined in cell extracts using spectrophoto-
metric methods previously described [38,39]. Results are expressed as
units of activity (U)/citrate synthase activity (CS) (mean ± standard
deviation). Proteins of ﬁbroblasts homogenates were determined by
the Bradford procedure [40]. Complex II (succinate dehydrogenase,
SDH) activity was also visualized cytochemically in cell cultures grown
on coverglass as described [41].2.7. CoQ determination
Cell samples were lysed with 1% SDS and a mixture of
ethanol:isopropanol (95:5). In order to recover CoQ we used hexane
and several centrifugations at 1000 ×g for 5 min at 4 °C. The upper
phases from three extractions were recovered and dried using a rotary
evaporator. Lipid extracts were suspended in ethanol, dried in a speed-
vac and stored at−20 °C up to the HPLC analysis (Shimadzu, Kyoto,
Japan). CoQ levels were determined with an ultraviolet detector.
Coenzyme Q9 (CoQ9) was used as an internal standard. CoQ content
was expressed as pmol/mg protein [42].2.8. Measurement of intracellular generation of reactive oxygen species
(ROS)
Flow-cytometric analysis of the intracellular generation of ROS was
performedusingMitoSOXTMRed (Invitrogen/Molecular Probes, Eugene,
OR, USA), a ﬂuorochrome speciﬁc for anion superoxide generated inmi-
tochondria. Cells were cultured in 6-well plates (35mmdiameter well)
and, at conﬂuence, incubated withMitoSOXTM Red (5 μM) for 30min at
37 °C. After incubation cells were harvested and analyzed by ﬂow
cytometry (FACScaliburTM, BD Biosciences, San Jose, CA, USA).2.9. Mitochondrial mass
Mitochondrial mass was determined by ﬂow cytometry after stain-
ing the cells with 10 μM Nonyl-Acridine orange (NAO) for 10 min at
37 °C in the dark. NAO speciﬁcally binds to cardiolipin and it is used to
estimate mitochondrial mass. However, it has been reported that NAO
ﬂuorescence is dependent upon mitochondrial membrane potential
[43]. To determine whether NAO binding was dependent onmitochon-
drial potential, NAO ﬂuorescence was determined in the absence and
presence of the uncoupler FCCP (1 μM). Mitochondrial mass was also
estimated bymeasuring citrate synthase activity. Cellular homogenates
were incubated for 2min with a solution 75mMTris–HCl pH 8, 1mM
5,5-dithiobis(2-nitrobenzoate) (DTNB), 0.1% Triton X-100 and
350 mg/ml acetyl CoA. After incubation 500 μM oxaloacetate was
added. The increase in absorbance was used to calculate citrate syn-
thase activity [38,44].2.10. Mitochondrial membrane potential (ΔΨm) determination
To estimate ΔΨm, control and MELAS ﬁbroblasts were exposed
to 0.5 μM tetramethylrhodamine ethyl ester (TMRE) or 0.5 μM JC-1
(Molecular Probes; Invitrogen, Carlsbad, CA, USA). Approximately
1 × 106 cells were trypsinized, incubated with TMRE or JC-1 for
20 min at 37 °C, washed twice with PBS, resuspended in 500 μl of PBS,
and analyzed by ﬂow cytometry. Both probes, TMRE and JC-1, were
excited with the 488 nm argon laser. Signals from TMRE ﬂuorescence
were collected through the FL1 detector (525 ± 5 nm band pass ﬁlter).
The ﬂuorescence signals of JC-1monomers and aggregates were detect-
ed through the FL1 (525 ± 5 nm band pass ﬁlter) and FL2 channels
(575 ± 5 nm band pass ﬁlter), respectively.
To conﬁrm the results of the TMRE and JC-1 analysis, cells were
stained with 100 nM MitoTracker Red CMXRos (Molecular Probes;
Invitrogen) for 30 min at 37 °C, washed, and ﬁxed with 4% paraformal-
dehyde for 10min at room temperature. After washing, cells were visu-
alized using a DeltaVision system (Applied Precision; Issaquah, WA,
USA) with an Olympus IX-71 microscope.2.11. Mitochondrial morphology assessment
Mitochondrial size and shape were quantiﬁed by ImageJ (NIH)
software. Mitochondria that were longer than 0.5 μm were deﬁned as
tubular mitochondria. To assure accuracy in the scoring process, mito-
chondrial size and shape were determined and analyzed independently
by two investigators. More than 200 clearly identiﬁable mitochondria
from 50 cells per experiment, randomly selected, were measured in
three independent experiments.2.12. Lysosomal content assay
Cells were cultured in 6-well 35 mm plates, until conﬂuence.
Next, cells were incubated for 30 min with 75 nM LysoTracker™
Red (Invitrogen/Molecular Probes) a ﬂuorophore which is concen-
trated in cell acidic vacuoles. After incubation, cells were washed,
and the red ﬂuorescence of LysoTracker™ was measured by ﬂow
cytometry.2.13. ATP/ADP quantiﬁcation assay
ATP and ADP levels were assayed by using a luciferase-based assay,
according to the instructions of themanufacturer (ADP/ATP Ratio Assay
Kit, Sigma-Aldrich), using a Tuner Designs Luminometer TD 20/20
(Sunnyvale, CA, USA).
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Western blotting was performed using standard methods. After
protein transfer, themembranewas incubatedwith various primary an-
tibodies at a 1:1000 dilution, and then with the corresponding second-
ary antibody coupled to horseradish peroxidase at a 1:2500 dilution.
Speciﬁc protein complexes were identiﬁed using the Immun Star HRP
substrate kit (Biorad Laboratories Inc., Hercules, CA, USA).
2.15. Cell fractionation and isolation of nuclear proteins
After treatments, cells were pelleted and washed using buffer A
(10 mM Hepes-KOH pH 7.9, 15 mM MgCl2, 10 mM KCl). Then, cells
were centrifuged 5 min at 13,000 rpm 4 °C. While supernatant was
discarded (cytoplasmic proteins), the pellet was resuspended in buffer
B (20 mM Hepes-KOH pH 7.9, 1.5 mM MgCl2, 25% Glycerol, 0.2 mM
EDTA, 420 mM NaCl) and incubated 20 min on ice. Buffers A and B
were supplemented with 1 mM DTT, 0.5 mM PMSF, 1 mM NaF and
1 mM sodium orthovanadate. Finally, we centrifuged the solution for
2min at 13,000 rpm and nuclear proteins (supernatant)were collected.
Nuclear proteins were frozen in liquid nitrogen and stored as aliquots
at−80 °C until further analysis.
2.16. Immunoﬂuorescence microscopy
Fibroblasts were grown on 1 mm glass coverslips (Thermo
Scientiﬁc™ Gold Seal™, Waltham, MA, USA). Cells were rinsed once
with PBS, ﬁxed in 3.8% paraformaldehyde for 10 min at room tempera-
ture, andpermeabilizedwith 0.1% saponin for 10min. For immunostain-
ing, glass coverslips were incubated with primary antibodies diluted
1:100 in PBS. Secondary antibodies were diluted 1:100 in PBS and
added on the coverslip. The samples were incubated for 1 h at 37 °C.
Coverslips were then rinsed with PBS, incubated for 10 min with
Hoechst 33342 (1 mg·ml−1) and washed with PBS (3 times 5 min).
Finally, the coverslips were mounted onto microscope slides using
Vectashield Mounting Medium (Vector Laboratories, Burlin-game, CA,
USA) and analyzed using an upright ﬂuorescence microscope (Leica
DMRE, Leica Microsystems GmbH, Wetzlar, Germany). Deconvolution
studies and 3D projections were performed using a DeltaVision system
(Applied Precision; Issaquah, WA, USA) with an Olympus IX-71
microscope.
2.17. Mitophagy analysis
Mitophagy analysis was performed by LC3B and cytochrome c immu-
nostaining. Colocalization analysis was assessed using the DeltaVision
software and calculating the Pearson's coefﬁcient of correlation. Rounded
and fragmented mitochondria resulted usually in mitophagic events.
Positive punctata (LC3B/cytochrome c positive) were considered when
Pearson´s coefﬁcient of correlations were higher than 0.75. Mitophagic
cells were scored when more of 10 punctata were observed in the cells.
Datawere represented asmitophagic cellswith respect to totalmeasured
cells. Results are expressed as mean ± SD.
2.18. Proliferation assay
Cells were seeded (N0) in 6-well plates. After a week of incubation
cells were harvested and cells were quantiﬁed (N) by using a conven-
tional Neubauer counter chamber. Cell viability was assessed by trypan
blue exclusion. Proliferation rate (n)was calculated by using the formu-
la N = N0 × 2n. Results are expressed as mean ± SD.
2.19. Electron microscopy
Electron microscopy was performed using a protocol previously
described by our group [42]. For quantiﬁcation of autophagic vesiclesper 10 μm2 of cytoplasma, the number of autophagosomes and
autophagolysosomes were scored in 50 cells. Data are presented as
mean ± SD.
2.20. Statistical analysis
All results are expressed asmean± SD, unless stated otherwise. The
measurements were statistically analyzed using Student's t-test for
comparing two groups and ANOVA for more than two groups. P-values
of less than 0.05 were considered signiﬁcant.
3. Results
3.1. Mitophagy activation in MELAS ﬁbroblasts
Pathophysiological alterations were characterized in primary
culture ﬁbroblasts derived from four different MELAS patients (MELAS
1, MELAS 2, MELAS A, MELAS B) carrying the m.3243ANG mutation
with different mutation load (MELAS 1: 17%, MELAS 2: 26%, MELAS A:
9% and MELAS B: 4%) and control ﬁbroblasts derived from healthy
volunteers.
As mitochondrial dysfunction and degradation of impaired mito-
chondria have been reported in MELAS ﬁbroblasts [13,14], we ﬁrst
assessed if mitophagic activation was a general phenomenon in the
four MELAS ﬁbroblasts cell lines. As lysosomal content is usually
increased when autophagy is activated, we quantiﬁed the amount of
acidic vesicles using Lysotracker Red® staining and ﬂow cytometry
analysis. Lysosomal content was signiﬁcantly increased in the four
MELAS ﬁbroblasts cell lines with respect to control ﬁbroblasts
(Fig. 1A). Given that mitophagy needs the autophagy machinery we
next determined the protein expression levels of well-known autopha-
gic markers and mediators such as ATG12–ATG5 conjugated and LC3B-
II. As shown in Fig. 1 andC, ATG12–ATG5 conjugated and LC3B-II protein
expression levels were higher in MELAS ﬁbroblasts than in control cells
suggesting autophagy activation.
Then, we assessed if mitochondria were selectively degraded by
mitophagy in MELAS ﬁbroblasts. Mitophagy was detected by labelling
amitochondrial protein as cytochrome c and an autophagosome associ-
ated protein as LC3B. In this experiment, we used cytochrome c as ami-
tochondrial marker to assess the speciﬁcity of MitoTracker staining and
to verify thatmitochondrial depolarization inMELASﬁbroblastswas not
a result of cytochrome c release, as occurs in apoptosis. Colocalization of
LC3B/cytochrome c proteins was found in the four MELAS cell lines
indicating the activation of the selective degradation of mitochondria
(Fig. 1E, D and F). Colocalization studies also revealed that high
LC3B/cytochrome c colocalization was detected in the small rounded
fragmented mitochondria population (white arrows) while it was not
observed in the normal tubular mitochondrial network (red arrows)
(Fig. 1F). Mitophagy activation inMELAS ﬁbroblasts was also conﬁrmed
by electron microscopy (Supplementary Fig. 1).
To check for autophagosome maturation and autophagic ﬂux in
MELAS ﬁbroblasts, we used baﬁlomycin A1, a speciﬁc inhibitor of vacu-
olar H+-ATPases and a blocker of autophagosome-lysosome fusion.
Control and MELAS ﬁbroblasts were incubated for 12 h in the presence
of baﬁlomycin A1. As expected, baﬁlomycin A1 treatment in control
ﬁbroblast cells led to a signiﬁcant increase in the LC3B II/LC3 B I ratio,
suggesting that autophagic ﬂux is normal in control cells (Supplementa-
ry Fig. 2). However, baﬁlomycin A1 treatment in MELAS 1 ﬁbroblasts
had no effect on LC3B II/LC3 B I ratio, indicating that autophagic ﬂux
was severely impaired in MELAS 1 ﬁbroblasts with high heteroplasmy
load (Supplementary Fig. 2). In contrast, baﬁlomycin A1 treatment in
MELAS B ﬁbroblasts had a slight effect on LC3B II/LC3B I ratio, indicating
that autophagic ﬂux was moderately impaired in MELAS B ﬁbroblasts
with low heteroplasmy load (Supplementary Fig. 2).
The colocalization of mitochondrial and autophagosomal markers
analysis also showed that MELAS 1 and MELAS 2 ﬁbroblasts frequently
Fig. 1.Mitophagy inMELAS ﬁbroblasts. (A) Quantiﬁcation of acidic vacuoles in control andMELAS ﬁbroblasts by Lysotracker staining and ﬂow cytometry analysis. Results are expressed as
ﬂuorescence intensity (mean channel). For the control cells the data are the means± SD for experiments conducted on two different control cell lines. Data represent the mean ± SD of
three separate experiments. (B) Protein expression levels of LC3B I (upper band) and LC3B II (lower band), and ATG12–ATG5 conjugatedwere determined in control andMELASﬁbroblast
cultures byWestern blotting as described inMaterial andmethods. (C) Densitometry (a.u., arbitrary units) ofWestern blottingwas performedusing the ImageJ software. GAPDHwas used
as a loading control. Data represent themean± SD of three separate experiments. (D)Mitophagy quantiﬁcation in control andMELAS ﬁbroblasts. Mitophagic cells are scoredwhenmore
of 10 punctata (LC3B/cytochrome c positive) are observed in the cells. (E) Immunostaining of cytochrome c and LC3B. Cultured Control and MELAS ﬁbroblasts were ﬁxed, and immuno-
stained with anti-LC3B (autophagosome marker) and cytochrome c (mitochondrial marker) and examined by ﬂuorescence microscopy as described in Material and Methods.
(F) Magniﬁcation of a small area in a MELAS A ﬁbroblast and colocalization analysis of cytochrome c/LC3B II in autophagosomes. With red arrows are shown mitochondria with low
colocalization and with white arrows rounded/fragmented mitochondria with high colocalization. Colocalization of both markers was assessed by the DeltaVision software calculating
the Pearson's correlation coefﬁcient. The results were expressed as mean ± SD. *P b 0.05, **P b 0.01, ***P b 0.001 between control and MELAS ﬁbroblasts.
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chondrial network, while MELAS A and MELAS B ﬁbroblasts showed
mitophagy activation but also a rich mitochondrial tubular network
(Fig. 1E and F). These results may suggest that mitochondrial biogen-
esis activation was compensating mitochondrial degradation inMELAS A and MELAS B ﬁbroblasts but not in MELAS 1 and MELAS 2
ﬁbroblasts.
Mitochondrial membrane potential (ΔΨm) is usually a good
marker of proper mitochondrial function while mitochondria depo-
larization is a well-known signal of mitochondrial dysfunction that
Fig. 2.Mitochondrial membrane potential inMELAS ﬁbroblasts. (A) Flow cytometry analysis ofmitochondrial membrane potential by TMRE staining of control andMELAS ﬁbroblasts. For
the control cells the data are the means ± SD for experiments on two different control cell lines. Data represent the mean ± SD of three separate experiments. (B) Visualization of
mitochondria andΔΨm byMitoTracker Red CMXRos and cytochrome c staining in control andMELASﬁbroblasts by ﬂuorescencemicroscopy as described inMaterial andmethods. Nuclei
were revealed byHoechst staining. Bar= 5 μm.Magniﬁcation of a small area in Control (C)MELAS 1 (D) andMELAS A ﬁbroblasts (E). Cyan arrows point out hyperpolarizedmitochondria
network and white arrows the small rounded depolarized mitochondria. The results were expressed as mean ± SD. *P b 0.001 between control and MELAS ﬁbroblasts.
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by ﬂow cytometry using TMRE. We found that ΔΨm was reduced by
50–60% in the four MELAS ﬁbroblasts cell lines with respect to con-
trol ﬁbroblasts (Fig. 2A). Mitochondrial depolarization in MELAS ﬁ-
broblasts was also veriﬁed by using the ratiometric probe JC-1
(Supplementary Fig. 3).
To conﬁrm that the changes in ΔΨmwere the result of mitochon-
drial polarization and not caused by alterations in mitochondrial
mass or proliferation, individual mitochondria were examined in
control andMELAS ﬁbroblasts by ﬂuorescencemicroscopy. MitoTracker
and cytochrome c staining and examination of individual mitochondria
conﬁrmed the presence of depolarized mitochondria in the four MELAS
ﬁbroblasts cell lines with respect to control ﬁbroblasts (Fig. 2B). While
control ﬁbroblasts show a normal polarized mitochondrial tubular net-
work (Fig. 2C), two populations of mitochondria with different polari-
zation levels were observed in the four MELAS cell lines. Fig. 2D and E
show that MELAS 1 and MELAS A ﬁbroblasts content mitochondria
with different polarization levels as indicatedwith white (low polariza-
tion) and cyan arrows (high polarization). Representative high sizeimages ofMELAS 2 ﬁbroblasts stained withMitoTracker and quantiﬁca-
tion of mitochondrial network are showed in Supplementary Fig. 4.
Mitophagy inMELAS ﬁbroblasts was associated with Parkin translo-
cation to depolarized mitochondria, which is a well established mecha-
nism for the selective elimination of mitochondria in mammalian cells
(Supplementary Fig. 5).
3.2. Differential pathophysiology in MELAS ﬁbroblasts
To further examine the pathophysiological alterations in MELAS
ﬁbroblasts, we analyzed proliferation rate, ATP and ADP levels, respira-
tory chain enzyme activities, CoQ levels and reactive oxygen species
production, as indicators of mitochondrial function. Results revealed a
differential pathophysiological severity among the four MELAS ﬁbro-
blasts cell lines. Proliferation rate assays shows the growth capacity of
the different ﬁbroblasts cultures. High growth levels were considered
as a signal of proper cellular function. On the contrary, low growth
rateswere considered as a lack of optimumcellular conditions. Twopat-
terns of growth rates were observed in MELAS ﬁbroblasts. Growth rate
Fig. 3.Differential pathophysiology inMELAS ﬁbroblasts. (A) Proliferation rate was determined by quantifying the number of cells after a week of incubation. (B) ATP and ADP levelswere
measured using a commercial kit as describe in Material and methods and the results are expressed as ATP/ADP ratio. (C) Reactive oxygen species levels were measured using MitoSOX
staining coupled with ﬂow cytometry analysis. The results are expressed as ﬂuorescence intensity (mean channel). (D) CoQ levels were determined by HPLC as described inMaterial and
methods. The results are expressed in pmol CoQ/mg protein. For the control cells the data are the means ± SD for experiments on two different control cell lines. Data represent the
mean± SD of three separate experiments. (E)Western blotting ofmitochondrial respiratory chain (MRC) proteins. Protein extracts (50 μg)were separated on a 12.5% SDS polyacrylamide
gel and immunostained with antibodies against complex I (ND1) and complex II (30 kDa subunit), complex III (core 1 subunit) and complex IV (subunit 1). Actin was used as loading
control. (F) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ. Results are expressed as mean ± SD. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance
of MELAS with respect to control ﬁbroblasts; aP b 0.05; bP b 0.01; cP b 0.001 signiﬁcance of MELAS A and MELAS B ﬁbroblasts with respect to MELAS 1 and MELAS 2 ﬁbroblasts.
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whereas it was near to control values in MELAS A andMELAS B cultures
(Fig. 3A). As low proliferation rate could be explained as a lack of energy
production to support proper cell division, we determined ATP/ADP
ratio in control and MELAS ﬁbroblasts. ATP/ADP ratios were notably
decreased in MELAS 1 and MELAS 2 while they were not signiﬁcantly
altered in MELAS A and MELAS B ﬁbroblasts (Fig. 3B). Since energy-production in MELAS 1 and MELAS 2 cultures was impaired, we next
examined if this alteration could be associated with mitochondrial
dysfunction. As mitochondrial dysfunction is associated with increased
reactive oxygen species (ROS) production in mitochondria, we exam-
ined ROS levels in MELAS cultures by ﬂow cytometry using MitoSOX
as a mitochondrial superoxide sensor. ROS levels were increased by
5–7 fold in MELAS 1 and MELAS 2 ﬁbroblasts whereas they were close
Fig. 4.Mitochondrial respiratory chain complex enzyme activities in control and MELAS ﬁbroblasts. (A) NADH:coenzyme Q1 oxidoreductase (complex I) activity. (B) Succinate dehydro-
genase (complex II) activity. (C) Ubiquinol:cytochrome c oxidoreductase (complex III) activity. (D) Cytochrome c oxidase (complex IV) activity. (E) NADH: cytochrome c reductase
(complex I + III) activity. (F) Succinate:cytochrome c reductase (complex II + III) activity. Mitochondrial respiratory chain complex enzyme activities were determined as described in
Material andmethods. For the control cells the data are themeans± SD for experiments on two different control cell lines. Data represent themean± SD of three separate experiments.
Results are expressed asU/CS (mean±SD). *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance ofMELASwith respect to control ﬁbroblasts; aP b 0.05; bP b 0.01; cP b 0.001 signiﬁcance ofMELAS
A and MELAS B ﬁbroblasts with respect to MELAS 1 and MELAS 2 ﬁbroblasts.
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sults suggest that mitochondria dysfunction severity and the proper ac-
tivation of the cellular antioxidant system may participate in the
differential pathophysiology showed in the four MELAS cell lines.
CoQ is a fundamental component of the mitochondrial respiratory
chain (MRC) transporting electrons from complexes I and II to complex
III. As CoQ deﬁciency has been recently detected in mitochondrial
diseases caused by mtDNA mutations [47], we next determined CoQ
levels in MELAS ﬁbroblasts. CoQ levels were reduced by 50% with
respect to controls in MELAS 1 and MELAS 2 ﬁbroblasts. However, CoQ
levels were increased by 1.7–2.7 fold in MELAS A and MELAS B ﬁbro-
blasts, respectively (Fig. 3D). These data indicate the presence of a
CoQ deﬁciency in MELAS 1 and MELAS 2 but not in MELAS A and
MELAS B ﬁbroblasts.
To further assess the functional consequences of this differential
pathophysiology, we analyzed mitochondrial protein expression levels
by immunoblotting in control and MELAS ﬁbroblasts. As shown in
Fig. 3E and F, MELAS 1 and MELAS 2 showed a signiﬁcant reduction in
mitochondrial protein expression levels. Complex I was reduced by
~40%, Complex II by ~75%, Complex III by ~70% and Complex IV by~73%. However, MELAS A and MELAS B showed higher expression
levels of mitochondrial complexes proteins which were near to control
values.
To further conﬁrm if reduced mitochondrial protein expression
levels had an effect onmitochondrial function,wemeasured respiratory
chain enzymes activity in control and MELAS ﬁbroblasts. The activity of
all of the mitochondrial respiratory chain complexes were signiﬁcantly
reduced in MELAS 1 and MELAS 2 ﬁbroblasts (Fig. 4). Complex IV activ-
ity, the most altered, was reduced by ~73% (Fig. 4D). Complex I activity
was reduced by 62 and 52% with respect to control values in MELAS 1
and MELAS 2 ﬁbroblasts, respectively (Fig. 4A). Complex II activity
was reduced by ~50% with respect to control values (Fig. 4B). Complex
I + III activity and complex II + III were reduced by ~35% and 60% in
MELAS 1 and MELAS 2 respectively (Fig. 4E and F). Complex III activity
was reduced by ~75% and 60% in MELAS 1 and in MELAS 2, respectively
(Fig. 4C). These results support previous publications which reported a
reduction in mitochondrial respiratory chain enzymatic activities in
MELAS cells. The main part of the literature reports a decrease in com-
plex I and IV activities [48–50], but there are also publications of alter-
ations of complex II [51] or complex III activities [52]. On the contrary,
Fig. 5.Mitochondrial biogenesis analysis in control andMELASﬁbroblasts. (A)Mitochondrial massmeasured byNonyl acridine orange staining and ﬂow cytometry analysis in control and
MELAS ﬁbroblasts. For the control cells the data are the means ± SD for experiments on two different control cell lines. Data represent the mean ± SD of three separate experiments
(B) Mitochondrial mass measured by citrate synthase speciﬁc activity expressed as units (μmol/ml/min)/mg protein in control and MELAS ﬁbroblasts. (C)Western blotting of regulatory
proteins involved inmitochondrial biogenesis (PGC-1α, NRF1 andmtTFA) in control andMELASﬁbroblasts. GAPDHwas used as loading control. (D) Densitometry (a.u., arbitrary units) of
Western blottingwas performed using ImageJ software. (E)Western blotting ofMn-SOD, catalase and total and phosphorylated AMP-activated protein kinase (Total-AMPK and Phospho-
AMPK, respectively) in control and MELAS ﬁbroblasts. (F) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ software. GAPDHwas used as loading
control. Results are expressed asmean± SD. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance ofMELASwith respect to control ﬁbroblasts; aPb0.05; bPb0.01; cPb0.001 signiﬁcance ofMELAS
A and MELAS B ﬁbroblasts with respect to MELAS 1 and MELAS 2 ﬁbroblasts.
2543J. Garrido-Maraver et al. / Biochimica et Biophysica Acta 1852 (2015) 2535–2553mitochondrial respiratory chain enzymatic activities were near or even
higher than control values in MELAS A and MELAS B ﬁbroblasts.
Both mitochondrial protein expression levels and respiratory chain
activities of complex II were partially restored in MELAS 1 and MELAS
2 after baﬁlomycin A1 treatment, indicating that excessive lysosomal
degradation was indeed the cause of mitochondrial protein and func-
tion loss (Supplementary Fig. 6).
All together, these results suggest, as expected, that MELAS 1 and
MELAS 2 ﬁbroblasts harbouring high mutation load express a more
severe pathological phenotype than MELAS A and MELAS B ﬁbroblasts
with low mutation load.
3.3. Mitochondrial biogenesis as a compensatory mechanism in MELAS
ﬁbroblasts
When mitophagy was examined (Figs. 1 and 2), a rich proliferating
tubular mitochondrial network was found in MELAS A and MELAS B
ﬁbroblasts but not in MELAS 1 and MELAS 2 ﬁbroblasts. We then
hypothesized that mitochondrial biogenesis was properly activated in
MELAS A and MELA B ﬁbroblasts in order to compensate mitochondrialdegradation, but this compensatory mechanism was less efﬁcient or
absent in MELAS 1 and MELAS 2 ﬁbroblasts. To verify this hypothesis,
we examined mitochondrial mass in MELAS ﬁbroblasts by determining
the amount of cardiolipin in mitochondrial membranes using nonyl
acridine orange in the presence of an uncoupling agent (FCCP) and
ﬂow cytometry analysis. We found that mitochondrial mass was
reduced by ~50% in MELAS 1 and MELAS 2 ﬁbroblasts with respect to
control ﬁbroblasts. On the contrary, mitochondrial mass was higher in
MELAS A and MELAS B with respect to control levels (Fig. 5A). Mito-
chondrial mass was also assessed by determining citrate synthase activ-
ity, a mitochondrial matrix enzyme whose activity correlates with
mitochondrial mass [53]. As shown in Fig. 5B, citrate synthase activity
was signiﬁcantly reduced by ~50% in MELAS 1 and ~65% in MELAS 2 ﬁ-
broblasts. On the contrary, citrate synthase activity was near to control
values in MELAS A and MELAS B ﬁbroblasts. These results suggest that
mitochondrial proliferation was able to compensate mitochondrial
elimination in MELAS A and MELAS B but not in MELAS 1 and MELAS
2 ﬁbroblasts.
To conﬁrm these ﬁndings, we examined protein expression levels of
three key proteins involved in mitochondrial biogenesis: peroxisome
Fig. 6. Effect of AICAR or CoQ treatment onMELASﬁbroblasts. Control andMELAS ﬁbroblastswere supplementedwith 100 μMAICAR or 100 μMCoQ for aweek. (A) Effect of AICAR or CoQ
treatment on proliferation rate in control and MELAS ﬁbroblasts was analyzed by counting viable cells as described inMaterial andmethods. (B) Effect of AICAR or CoQ treatment on ROS
levelsmeasured byMitoSOX staining and ﬂowcytometry analysis. (C) Effect of AICAR or CoQ treatment in control andMELASﬁbroblasts onmitophagy examined by quantifying cellswith
cytochrome c and LC3 positive punctata. Mitophagic cells were scored whenmore of 10 punctata (LC3B/cytochrome c positive) are observed in the cells. (D) Effect of AICAR or CoQ treat-
ment on citrate synthase activity in control, MELAS 1 andMELAS A ﬁbroblasts. (E) Effect of AICAR or CoQ treatment on ATP levels in control, MELAS 1 andMELAS A ﬁbroblasts. All results
were expressed as mean ± SD. Results are expressed as mean ± SD of three independent experiments. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance of MELAS with respect to control
ﬁbroblasts. aP b 0.05; bP b 0.01; cP b 0.001, signiﬁcance ofMELASA andMELAS Bﬁbroblastswith respect toMELAS1 andMELAS2ﬁbroblasts. #P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance
between the presence or absence of AICAR or CoQ treatment.
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nuclear respiratory factor 1 (NRF-1) and mitochondrial transcriptional
factor A (mtTFA) expression levels were signiﬁcantly decreased in
MELAS 1 andMELAS 2 ﬁbroblasts whereas they were notably increased
inMELAS A andMELAS B ﬁbroblasts (Fig. 5C and D). PGC-1α and NRF-1
protein expression levels in MELAS A and MELAS B were even higher
than in control ﬁbroblasts. The expression levels of mtTFA in MELAS A
and MELA B were increased with respect to MELAS 1 and MELAS 2 but
not higher than control levels. These results support the hypothesis
that high expression levels of proteins involved in mitochondrial
biogenesis are necessary to maintain high mitochondria mass for com-
pensating mitochondria loss by mitophagy in MELAS A and MELAS Bﬁbroblasts. However this compensatory mechanism was not efﬁciently
activated in MELAS 1 and MELAS 2 ﬁbroblasts.
3.4. Enzymatic anti-oxidant system and AMP-activated protein kinase
(AMPK)
ROS are mainly produced as a result of mitochondrial dysfunction
[54]. Speciﬁcally, one main contributor to oxidative stress is hydrogen
peroxide (H2O2),which is derived fromsuperoxide (O2−) generated inmi-
tochondria. The toxic effects of H2O2 and O2− are prevented by catalase
and superoxide dismutase that convert these compounds into H2O and
O2. While ROS are normally produced in the normal cellular respiration,
Fig. 7. Effect of AICAR or CoQ treatment onAMPK activation, enzymatic antioxidant system, PGC-1α and LC3B expression levels. Control andMELAS 1ﬁbroblastswere treatedwith 100 μM
AICAR or 100 μM CoQ for one week. (A) Western blotting of phospho-AMPK, total-AMPK, Mn-SOD, Catalase, PGC-1α and LC3B in control and MELAS 1 ﬁbroblasts. GAPDH was used as
loading control. (B, C, D, E, F) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ software. All results were expressed as mean ± SD of three inde-
pendent experiments. The cultures were supplemented with AICAR and CoQ for 1 week. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance of MELAS with respect to control ﬁbroblasts.
#P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance between the presence or absence of AICAR or CoQ treatment.
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sensor proteins as AMPK are required for the activation of the defensive
anti-ROS system [55]. Therefore, we examined the protein expression
levels of different proteins involved in ROS-scavenging. Catalase and mi-
tochondrial manganese superoxide dismutase (Mn-SOD) expression
levels were increased in MELAS A and MELAS B ﬁbroblasts with respect
to controlﬁbroblasts (Fig. 5E andF). On the contrary, the expression levels
of both enzymes were dramatically decreased in MELAS 1 and MELAS 2
with respect to control ﬁbroblasts. These results suggest that proper acti-
vation of the enzymatic antioxidant system response is achieved in
MELAS A and MELAS B but not in MELAS 1 and MELAS 2 ﬁbroblasts.
Finally, given that AMPKactivation is awell-known inducer of catalase
and Mn-SOD expression levels we also examined the phospho-AMPK/
total-AMPK ratio in MELAS ﬁbroblasts. Phospho-AMPK/total-AMPK ratio
was increased in MELAS A and MELAS B but not in MELAS 1 and MELAS
2. In fact a decrease by ~35–40% in MELAS 1 and MELAS 2 was found
with respect to MELAS A and MELAS B ﬁbroblasts (Fig. 5E and F).
3.5. Pharmacological stimulation of MELAS ﬁbroblasts with AICAR and CoQ
As pathophysiological studies revealed that MELAS 1 and MELAS 2
ﬁbroblasts with high heteroplasmy load showed severe mitochondrialdysfunction associated with high ROS production, decreased mito-
chondrial mass, impaired enzymatic antioxidant system response
and inappropriate AMPK activation, we then studied the effective-
ness of AMPK activation by AICAR and CoQ treatment on MELAS ﬁ-
broblasts pathophysiological alterations. AICAR, an AMP analogue,
activates AMP-activated protein kinase (AMPK). AMPK acts as a
metabolic regulator that is activated in situations of low energy
availability (low ATP/ADP ratios). AICAR is transported into cells
by adenosine transporters and metabolized by adenosine kinase to
5-aminoimidazole-4-carboxamide ribonucleoside (ZMP), which
mimics all the effects of AMP on the AMPK system [56]. On the
other hand, CoQ or ubiquinone is a lipid-soluble molecule present
in cell membranes, mainly in the inner mitochondrial membrane.
CoQ transfers electrons from complexes I and II to complex III of
the mitochondrial respiratory chain; it also works as a ROS scaven-
ger, and it participates in many metabolic pathways including
AMPK activation [57–59].
Control and MELAS ﬁbroblast were treated with 100 μM AICAR or
100 μM CoQ and the improvement in pathophysiological alterations
was analyzed. Proliferation rate of MELAS 1 and MELAS 2 ﬁbroblasts
wasnotably increase after AICARor CoQ treatments (Fig. 6A). Especially,
the proliferation rate of MELAS 1 ﬁbroblasts treated with CoQ was the
Fig. 8. Effect of AICAR and CoQ treatment on nuclear PGC-1α localization in control andMELAS ﬁbroblasts. Control andMELAS ﬁbroblasts were treatedwith 100 μMAICAR or 100 μMCoQ
for one week. (A) Representative images of immunostaining of phospho-PGC-1α (red) visualized by ﬂuorescence microscopy in control andMELAS ﬁbroblasts. (B) Quantiﬁcation of ﬂuo-
rescent phospho-PGC-1α foci in the nuclei using ImageJ software.More than 100 randomly selected cells were analyzed for each experimental condition. Results are expressed asmean±
SDof three independent experiments. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance ofMELASwith respect to controlﬁbroblasts. aP b 0.05; bP b 0.01; cP b 0.001, signiﬁcance ofMELASA and
MELAS B ﬁbroblasts with respect to MELAS 1 and MELAS 2 ﬁbroblasts. #P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance between the presence or absence of AICAR or CoQ treatment.
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MELAS 1 and MELAS 2 ﬁbroblasts were signiﬁcantly decreased by 50%
after AICAR or CoQ treatments (Fig. 6B). AICAR and CoQ treatments
were also effective in decreasing autophagolysosome accumulation in
the fourMELAS cell lines (Fig. 6C). In addition, AICAR or CoQ treatments
were effective in improving mitochondrial mass in MELAS 1 ﬁbroblasts
determined by measuring citrate synthase activity and ATP levels in
MELAS 1 and MELAS A ﬁbroblasts (Fig. 6D and E). These results suggest
that both AICAR and CoQ treatments improved the pathophysiological
alterations in MELAS ﬁbroblasts, especially in those with a more severe
phenotype (MELAS 1 and MELAS 2).
To further characterization of the effect of AICAR and CoQ treatment,
we analyzed the protein expression levels byWestern blotting of sever-
al key proteins involved in mitochondrial biogenesis (PGC-1α), enzy-
matic antioxidant defence (Mn-SOD and catalase), regulators of bothpathways (as AMPK) and autophagosome accumulation (LC3B-II) in
MELAS 1 ﬁbroblasts with the most severe phenotype.
PGC-1α, Mn-SOD, catalase, and AMPK protein expression levels
were decreased in MELAS 1 ﬁbroblasts. The expression levels of
Mn-SOD and phospho-AMPK were the most affected proteins with
a 96% and 82% reduction, respectively (Fig. 7A, B, C, D and E). Catalase
and PGC-1α protein expression levels were reduced by 45% and 65%
respectively (Fig. 7D and E). AICAR or CoQ treatments restored PGC-
1α and catalase protein expression levels. AMPK protein band anal-
ysis also revealed the extra-phosphorylated forms of AMPK when
the medium was supplemented with AICAR or CoQ for a week
(Fig. 7A).
AICAR or CoQ treatments were also able to reduce autophagosome
accumulation in MELAS 1 ﬁbroblasts as assessed by reducing LC3B II
levels (Fig. 7A).
Fig. 9. Effect of AMPK inhibition on nuclear PGC-1α localization in MELAS 1 and MELAS A ﬁbroblasts. Control and MELAS 1 and MELAS A ﬁbroblasts were treated with 100 μM AICAR or
100 μMCoQ for one week in the presence or absence of 10 μM compound C, an AMPK inhibitor. (A) Quantiﬁcation of nuclear Phospho-PGC-1α foci using ImageJ software. More than 100
randomly selected cells were analyzed for each experimental condition. Results are expressed as mean ± SD. (B) Western blotting of phospho-PGC-1α in nuclear fractions.
(C) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ software. All results were expressed as mean ± SD of three independent experiments.
*P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance of MELAS with respect to control ﬁbroblasts. aP b 0.05; bP b 0.01; cP b 0.001, signiﬁcance of MELAS A and MELAS B ﬁbroblasts with respect
to MELAS 1 and MELAS 2 ﬁbroblasts. #P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance between the presence or absence of AICAR or CoQ treatment. $P b 0.05; $$P b 0.01; $$$P b 0.001,
signiﬁcance between the presence or absence of compound C.
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gy and autophagicﬂux,we then assessed if AICAR and CoQ treatments in
MELAS ﬁbroblasts were able to reduce autophagolysosome accumula-
tion by increasing autophagic ﬂux. Thus, control and MELAS ﬁbroblasts
pre-treated with AICAR or CoQ were incubated with the autophagic
ﬂux blocker baﬁlomycin A1 for 12 h and LC3B II expression levels were
examined byWestern blotting. Baﬁlomycin A1 incubation induced a sig-
niﬁcant increased on LC3-II expression levels in AICAR or CoQ treatedcontrol andMELASﬁbroblasts (Supplementary Fig. 7). These results sug-
gested that autophagic ﬂuxwas indeed increased byAICAR or CoQ treat-
ments. In fact, both AICAR and CoQwere able to increase the expression
levels and activation of the down-stream target ULK1, which is an acti-
vator of autophagy and required for proper autophagic ﬂux [60] (Sup-
plementary Fig. 8). Altogether, these data support the hypothesis that
AICAR and CoQ treatment reduce autophagosome accumulation in
MELAS cells by increasing autophagy clearance.
Fig. 10. Effect of AICAR and CoQ treatment on the pathophysiological alterations inMELAS cybrids. Control and MELAS cybrid cultures were supplemented with 100 μMAICAR or 100 μM
CoQ for 48 h. (A) Proliferation rate of control and MELAS cybrids was examined measuring the cell number as described in Material and methods. (B) ATP levels in control and MELAS
cybrids were measured using a Luciferase-based kit as described in Material and methods. (C) Western blotting of PGC-1α and LC3B in control and MELAS cybrids.
(D, E) Densitometry (a.u., arbitrary units) ofWestern blottingwas performedusing ImageJ software. All resultswere expressed asmean± SD. (F) Representative images of the subcellular
localization of phospho-PGC-1α in control andMELAS cybrids examined by ﬂuorescencemicroscopy. (G)Quantiﬁcation of nuclear phospho-PGC-1α fociwas performedusing ImageJ soft-
ware. More than 100 randomly selected cells were analyzed for each experimental condition. All results were expressed as mean ± SD of three independent experiments. *P b 0.05;
**P b 0.01; ***P b 0.001, signiﬁcance between MELAS cybrids (94aT3) with control cybrids (ACH). #P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance between the presence or absence of
AICAR or CoQ treatment.
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2549J. Garrido-Maraver et al. / Biochimica et Biophysica Acta 1852 (2015) 2535–2553PGC-1α is an essential regulator of mitochondrial biogenesis which is
also activated by AMPK. AMPK activation increases the expression of
PGC-1α mRNA [61] and also its activation by direct phosphorylation
[62]. On the other hand, there are evidences of nuclear PGC-1α transloca-
tion when it is phosphorylated by other proteins as Protein kinase A
(PKA). It seems that PGC-1α is a protein whose subcellular localization
is in the nucleus but is permanently interactingwith nuclear transporters
like CRM1 in order to be exported to the cytoplasm. Phosphorylation of
PGC-1α by PKA prevents nuclear export and increases PGC-1α in the
nucleus [63]. Therefore the subcellular localization seems to have great
importance for the functional activation of pathways like mitochondrial
biogenesis. Consequently, we analyzed the subcellular localization of
phospho-PGC-1α by immunostaining and ﬂuorescence microscopy
examination in the four MELAS ﬁbroblasts cell lines (Fig. 8A and B).
Phospho-PGC-1α predominantly showed cytoplasmic localization
in MELAS 1 and MELAS 2 ﬁbroblasts whereas a major presence of
phospho-PGC-1α in nuclei was observed in Control, MELAS A and
MELAS B ﬁbroblasts. We also quantiﬁed phospho-PGC-1α foci in nuclei
before and after a week of AICAR or CoQ treatments. We observed that
phospho-PGC-1α foci were signiﬁcantly increased in control, MELAS 1
and MELAS 2 cultures after AICAR or CoQ treatments (Fig. 8A and B).
To assess the role of AMPK in PGC-1α nuclear translocation after
AICAR or CoQ treatment, we quantiﬁed nuclear phospho-PGC-1α foci
in the presence or absence of compound C, a selective inhibitor of
AMPK. Phospho-PGC-1α nuclear foci were decreased after AICAR or
CoQ treatments in the presence of compound C in MELAS 1 and
MELAS A cell lines (Fig. 9A). These resultswere conﬁrmed by subcellular
fractionation techniques and the evaluation of phospho-PGC-1α
expression levels in the nuclear fraction by Western blotting (Fig. 9B
and C). The purity of the nuclear fraction was validated by Western
blot analysis of a “house-keeper” marker protein (Lamin B1) speciﬁc
for the nuclear compartment (Supplementary Fig. 9). Taken together
these data suggest that PGC-1α nuclear translocation is impaired in
MELAS 1 and MELAS 2 ﬁbroblasts and CoQ and AICAR treatment
increase nuclear phospho-PGC1-α foci through AMPK activation. Once
in the nucleus, phospho-PGC-1α is supposed to active mitochondrial
biogenesis and thus, compensating the deleterious defects of increased
mitophagy.
3.6. AICAR and CoQ also restored pathophysiological alterations in MELAS
cybrid cells harbouring the m.3243ANG mutation
Transmitochondrial cybrid cell lines are indispensable tools in mito-
chondrial investigation for providing a controlled nuclear background
in which to study the molecular mechanisms by which mutations in
mtDNA impair cellular function. Thus, the pathophysiological alter-
ations detected in the cybrids clones are supposed to be a function of
the dysfunctional mitochondria, independently of the nuclear context
[64].
To conﬁrm that AICAR and CoQ treatments were also effective in
MELAS cybrids harbouring the m3243ANG mutation, we examined
growth rate, ATP levels, expression levels of LC3 and PGC-1α in control
and MELAS cybrid clones. As shown in Fig. 10A growth rate of MELAS
cybrids was decreased with respect to control cybrids by 30% and it
was restored by AICAR and CoQ treatment (Fig. 10A). ATP levels were
signiﬁcantly decreased in MELAS cybrids and they were restored by
AICAR or CoQ treatments (Fig. 10B). The protein expression levels of
PGC-1α and LC3B were analyzed using Western blotting techniques
(Fig. 10C, D and E). We found increased values of LC3B and low expres-
sion levels of PGC-1α in MELAS cybrids which were restored to control
values by AICAR or CoQ supplementation. AICAR or CoQ treatments
also increased nuclear phospho-PGC-1α foci to normal values (Fig. 10F
and G).
Finally, we analyzed AMPK activation and the subcellular localiza-
tion of PGC-1α when AMPK was inhibited by compound C. Phospho-
AMPK expression levels were increased after AICAR or CoQ treatmentsand they were partially prevented by compound C (Fig. 11A and B).
AMPK inhibition also prevented the increased nuclear phospho-PGC-
1α foci after AICAR or CoQ treatments (Fig. 11C).
To further investigate the effect of AICAR and CoQ on mitochondrial
biogenesis in MELAS cybrids, we analyzed citrate synthase activity as a
measure of mitochondrial proliferation. Citrate synthase activity was
drastically reduced in MELAS cybrids. AICAR or CoQ treatment restored
citrate synthase activity that was partially prevented by AMPK inhibi-
tion by compound C (Fig. 11D). AICAR and CoQ were also able to
increase autophagy ﬂux in MELAS cybrids (Supplementary Fig. 10).
All together, these results suggest that both AICAR and CoQ effects
are mediated, at least partially, by AMPK activation.
4. Discussion
In this work, we showed the pathophysiological alterations in pri-
mary cultured ﬁbroblasts derived from 4 patients with MELAS disease
carrying the m.3243ANG mutation with different heteroplasmy load.
We found that MELAS ﬁbroblasts can be differenced according to their
pathophysiological alterations severity: a ﬁrst groupwith severe patho-
physiological alterations (MELAS 1 and MELAS 2), and a second group
with slight pathophysiological alterations (MELAS A and MELAS B).
MELAS ﬁbroblasts with high mutational load (MELAS 1 and MELAS
2) showed low growth rates, reduced ATP/ADP ratio and CoQ levels,
high ROS production and low enzymatic antioxidant system, dysfunc-
tional mitochondrial respiratory chain activities, mitophagy activation,
impaired autophagic ﬂux and poor tubular mitochondrial network
associated with low AMPK activation and PGC-1α, TFAM, and NRF1
down-regulation.
On the contrary, MELAS ﬁbroblasts with low mutational load
(MELAS A andMELAS B) also showedmitophagy activation butwithout
alterations of most of the pathophysiological parameters. MELAS A and
MELAS B showed a rich tubular mitochondrial network associated with
high AMPK activation and PGC-1α, TFAM, and NRF1 up-regulation and
manifest a similar phenotype to control ﬁbroblasts.
Furthermore, AICAR or CoQ supplementation reverts many of the
pathological alterations found in MELAS 1 and MELAS 2 ﬁbroblasts
with the more severe phenotype. The beneﬁcial effect of both AICAR
and CoQ seems to be mediated trough AMPK activation because it was
partially inhibited by compound C, an AMPK inhibitor. AICAR and CoQ
treatment induced AMPK activation and increased nuclear PGC-1α
translocation associated with increased mitochondrial biogenesis. All
together, these results suggest that AMPK activation by AICAR or CoQ,
in a context of low AMPK activity, is capable of compensating most of
the pathophysiological alterations in MELAS ﬁbroblasts. On the
contrary, inappropriate AMPK activation leads to impaired autophagic
ﬂux, autophagolysosome accumulation, inadequate antioxidant de-
fence, deﬁcient compensatorymitochondrial biogenesis and the expres-
sion of a more severe phenotype.
Our results suggest a critical balance between mitophagy and mito-
chondrial biogenesis in MELAS disease. Mitochondrial biogenesis may
work as an AMPK-mediated compensatory mechanism in response to
increased ROS production, reduced ATP levels andmitophagic degrada-
tion. Depending on the balance between both pathways, different
degrees of pathological alterations can be detected amongMELAS ﬁbro-
blasts cell lines. Thus, mitochondrial proliferation may work as a
compensatory mechanism triggered by the respiration defect [65]. As
mitophagy and mitochondrial biogenesis are two processes that
regulate mitochondrial content and preserve cell homeostasis [66],
the tight regulation between these pathways is crucial for cellular adap-
tation in response to cellular stress and other intracellular or environ-
mental signals. Interestingly, dysregulation between mitochondrial
biogenesis and mitophagy results in progressive development of nu-
merous diseases [66,67].
Wehypothesize that reducedphosphorylation of AMPK is responsible
for impaired autophagic ﬂux, poor compensatory response to mitophagy
Fig. 11. Effect of AICAR and CoQ treatment on AMPK activation inMELAS cybrids. Control andMELAS cybrid cultures were supplementedwith 100 μMAICAR or 100 μMCoQ for 1 week in
the presence or absence of 10 μM compound C, an AMPK inhibitor. (A) Western blotting of phospho-AMPK and total-AMPK in MELAS cybrids. Actin was used as loading control.
(B) Densitometry (a.u., arbitrary units) of Western blotting was performed using the ImageJ software. All results were expressed as mean ± SD. (C) Inmunostaining and subcellular lo-
calization of phospho-PGC-1α by ﬂuorescence microscopy in control and MELAS cybrids. Quantiﬁcation of nuclear phospho-PGC-1α foci was performed using ImageJ software. More
than 100 randomly selected cells were analyzed for each experimental condition. (D) Citrate synthase activity in control and MELAS cybrids. All results were expressed as mean ± SD
of three independent experiments. *P b 0.05; **P b 0.01; ***P b 0.001, signiﬁcance between MELAS cybrids with control cybrids. #P b 0.05; ##P b 0.01; ###P b 0.001, signiﬁcance between
the presence or absence of AICAR or CoQ treatment. $P b 0.05; $$P b 0.01; $$$P b 0.001, signiﬁcance between the presence or absence of compound C.
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state of MELAS ﬁbroblasts leading to a most severe phenotype.
A major challenge inMELAS disease is themoderate effectiveness of
pharmacological therapies; in this sense, AMPK activators such as AICAR
and CoQ, would provide new therapeutic opportunities. Based on these
ﬁndings, we suggest that a deeper understanding of the signaling
cascade induced by AMPK activation and its tissue-speciﬁc regulation
may provide new targets for the treatment of mitochondrial dysfunc-
tion related diseases and particularly in MELAS disease.
Mitophagy activation was also demonstrated in MELAS trans-
mitochondrial cybrids harbouring the A3243G mutation indicating thatas a consequence of themutation inmtDNA and not the product of a con-
comitant nuclear gene defect. MELAS cybrids also showed low AMPK ac-
tivation, reduced nuclear PGC-1α foci and severe pathophysiological
alterations that were restored by both AICAR and CoQ treatments.
AMPK is a serine/threonine kinase well conserved through evolu-
tion, and orthologs of the AMPK subunits have been found in all eukary-
otic species [68]. AMPK acts as an energy sensor of the cell andworks as
a key regulator of mitochondrial biogenesis [69]. Functionally, AMPK
activates pathways such as glycolysis and amino acid oxidation for
ATP production, while concurrently inhibits energy-dependent path-
ways such as biosynthesis of fatty acids and gluconeogenesis [70].
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decrease of the ATP/ADP ratio. Furthermore, it has been demonstrated
that AMPK could be also activated in response to elevatedmitochondri-
al ROS [71]. It has also been shown that skin ﬁbroblasts with MERRF
syndrome, another mitochondrial disease caused bymutations in mito-
chondrial tRNAs, produced high level of mitochondrial ROS associated
with AMPK activation [72].
But, whyAMPK is not properly activated inMELAS 1 andMELAS 2 ﬁ-
broblasts that showed low ATP/ADP ratios and high ROS production?
Currently, the mechanism to explain AMPK insensitivity is unknown.
We can speculate that these more severe phenotypes are caused by
decreased sensitivity of AMPK activation as it has been reported during
aging [73] and mitochondrial-related diseases as Fibromyalgia [74].The
loss of sensitivity of AMPK activation to bioenergetics imbalance and
cellular stress may aggravate oxidative stress and reduce autophagic
clearance and, as a result, MELAS cells show a more severe phenotype.
In response to oxidative stress elicited by mtDNAmutation-induced
mitochondrial dysfunction, AMPK activation (phosphorylation at
Thr172) would trigger several adaptive responses for cell survival
[75]. In response to oxidative stress, AMPK can directly phosphorylate
PGC-1α and FOXO3a, which in turn augment mitochondrial biogenesis
(e.g., up-regulation of mtTFA, NFR1, and NFR2) and the antioxidant de-
fence system response (e.g., the up-regulation ofMn-SOD and catalase).
In addition to antioxidant defence, AMPK has other effects on mito-
chondrial parameters as mitochondrial fusion and ﬁssion that have
emerged as important processes that govern mitochondrial function
[76–78]. Thus, a gain of function AMPK mutation in skeletal muscle
has been reported to increase the expression of mitochondrial fusion/
ﬁssion proteins, Mfn2, optic atrophy 1 (OPA1), and dynamin-related
protein 1 (Drp1) [79] which implicates AMPK in the regulation of
mitochondrial dynamics. Furthermore, AMPK functionally prevents
high-glucose induced mitochondrial ﬁssion in endothelial cells [80],
highlighting that AMPK activity promotesmitochondrial quality control
processes.
Furthermore, AMPK activation acts at multiple levels to stimulate
autophagy and autophagic ﬂux [81,82] and consequently may reduce
autophagolysosome accumulation in cellular contexts of increased
mitophagy.
All together these responses suggest that activation of AMPK plays
an essential role in the up-regulation of mitochondrial biogenesis,
antioxidant enzymes and autophagic ﬂux, as the adaptive and compen-
satory responses to mitochondrial dysfunction for the survival of affect-
ed cells.
Since AMPK is differentially activated inMELAS ﬁbroblast, AMPK ac-
tivation signaling pathway is worthy of further investigation in relation
to the pathophysiology of MELAS disease. In addition, considering
AMPK a potential therapeutic target, it is imperative to investigate
whether AMPK activators such as AICAR or CoQ or others, as resveratrol,
are beneﬁcial to patients with mitochondrial diseases in general and
MELAS disease in particular.
Detection of secondary CoQ deﬁciency in MELAS disease is particu-
larly interesting because CoQ supplementation can be an effective ther-
apy for the patients. Low CoQ levels can also function as a biochemical
marker of poor AMPK-dependent compensatory response in MELAS
ﬁbroblasts. Beneﬁts for CoQ supplementation include: increase in
mitochondrial electron transport and ATP production, improvement of
antioxidant protection, beneﬁcial alteration in redox signalling, andmi-
tochondrial permeability transition pore stabilization that may protect
against autophagy and apoptosis [83]. Our study suggests that CoQ
deﬁciency is the result of increasedmitophagywithout proper compen-
satory response bymitochondrial biogenesis as it is seen inMELAS 1 and
MELAS 2 ﬁbroblasts. Therefore, CoQ treatment could be effective by
alleviating the deﬁciency itself and by increasingmitochondrial biogen-
esis, the enzymatic antioxidant system response and autophagy
clearance through AMPK activation. It has been described that either in-
hibition of Ca2+/calmodulin-dependent protein kinase kinase (CaMKK)or knock-down CaMKK blocked CoQ-induced AMPK phosphorylation,
suggesting the involvement of calcium in CoQ-mediated AMPK signal-
ling [36]. CoQ also increased the expression of PGC-1α at both the
mRNA and protein levels. Knock down of AMPK with siRNA or inhibi-
tion of AMPK using an AMPK inhibitor (compound C) blocked CoQ-
induced expression of PGC-1α, indicating that AMPK plays a critical
role in PGC-1α induction by CoQ [36]. Recently, it has been proposed
that CoQ may activate Sirt1 and PGC-1α by increasing cyclic adenosine
monophosphate (cAMP) levels that, in turn, activate AMPK [84].
5. Conclusion
According to our data, (i) the lack of proper AMPK activation induces
a more severe phenotype in MELAS ﬁbroblasts, (ii) AMPK activation by
AICAR or CoQ restores most of the pathophysiological alterations. These
ﬁndings suggest that AMPK plays a central role in MELAS pathophysiol-
ogy and could become a new possible therapeutic target. Identiﬁcation
of AMPK as a regulating factor inMELAS pathophysiology is expected to
have signiﬁcant inﬂuence for future approaches in therapeutic and
monitoring management of MELAS patients.
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